doi: 10.1161/CIRCULATIONAHA.107.726992
(Circulation. 2007;116:e378-e382.)
© 2007 American Heart Association, Inc.
Clinician Update |
Coronary Stents and Noncardiac Surgery
From the Services de Cardiologie (J.W.R., M.H.), Chirurgie Digestive (L.C.), and Anesthesiologie (B.P.), University Hospital of Caen, Normandy, France.
Correspondence to Professor Martial Hamon, Service des Maladies du Coeur et des Vaisseaux, UF Soins Intensifs Cardiologiques, Centre Hospitalier Universitaire de Caen, Ave Côte de Nacre 14033 Caen, Normandy, France. E-mail hamon-m{at}chu-caen.fr
Key Words: angioplasty • stents • surgery • thrombosis
 |
Introduction |
|---|
 Top Introduction Noncardiac Surgery and Stent...Likely Clinical SettingsHow Should We Manage...ConclusionsReferences |
|---|
Case Presentation: A 55-year-old man was admitted for investigation of a persistent cough. Chest x-ray revealed an opacity near the right upper-lobe bronchus. He was an ex-smoker, and his only previous medical history was of an acute coronary syndrome leading to the implantation of a drug-eluting stent (DES) in his proximal left anterior descending artery 3 months before this admission. A transbronchial biopsy was required, so a discussion ensued between the cardiology and the respiratory teams about whether to stop his oral antiplatelet agents (OAAs), in this case, a combination of clopidogrel and aspirin.
|
Noncardiac Surgery and Stent Thrombosis |
|---|
|
TopIntroductionNoncardiac Surgery and Stent...Likely Clinical SettingsHow Should We Manage...ConclusionsReferences |
|---|
Interruption of OAA therapy, as often happens for noncardiac surgery, has been shown to be an important factor in stent thrombosis.1 The consequences of stent thrombosis are severe, with a 64% rate of death or myocardial infarction and a mortality rate of between 9% and 45%.1,2 In recent years, there has been an explosion in the use of DES, for which the risk of stent thrombosis, although likely to be similar to the standard bare-metal stent in the early phase, is less well defined owing to the longer, potentially indefinite period of time over which it may occur.3 Concern about the possible increased incidence of stent thrombosis with DES led to the publication of a consensus statement that highlighted the importance of not prematurely discontinuing dual OAA therapy and increasing its recommended duration in the case of DES to 1 year.4
The timing and definition of stent thrombosis vary between studies, which has led to a call for standardizing definitions.5 In addition, although most of the trials have included low-risk patients and coronary lesions, the use of DES in the real world is much less controlled, potentially increasing the risk of stent thrombosis.6,7
It has been well established that patients who undergo noncardiac surgery soon after stent implantation are at increased risk for stent thrombosis.8–10 The reasons for this increased risk may include nonendothelialization of the stent, interruption of dual OAA therapy, and the potentially prothrombotic state associated with surgery itself.
The risks of surgery after coronary stenting have been described in 8 observational, mainly retrospective, studies8–15 (summarized in Table 1). The mortality rate in such patients ranged from 2.5% to 21.4%.
|
Noncardiac surgery performed in patients who have had recent coronary stenting exposes them to an increased risk of major cardiac events in the perioperative period, especially if the OAA therapy is interrupted. Good theoretical reasons exist for delaying elective noncardiac surgery after coronary stenting, thereby allowing the stents to endothelialize.
|
Likely Clinical Settings |
|---|
|
TopIntroductionNoncardiac Surgery and Stent...Likely Clinical SettingsHow Should We Manage...ConclusionsReferences |
|---|
Two possible clinical scenarios exist for patients with stents who have noncardiac surgery. The first is the situation in which a patient requires noncardiac surgery and, as a result of a preoperative coronary risk assessment, undergoes an angiogram with subsequent stent implantation before the surgery is scheduled. The American College of Cardiology/American Heart Association guidelines clearly define patients who should undergo invasive coronary assessment.16 However, the advice about who should receive revascularization predates the use of DES and is based on normal, nonpreoperative practice. Therefore, some additional consideration may be warranted before preoperative revascularization is undertaken. In particular, consideration should be given to the urgency of the surgery and to the mode of revascularization, including, when applicable, the type of stent to be used. Since the publication of these guidelines, the Coronary Artery Revascularization Prophylaxis (CARP) trial, a randomized trial of coronary revascularization or not before vascular surgery, showed no difference in outcomes between groups.17 The study excluded patients with left main stem disease. The actual method of revascularization was not randomized and was
60% percutaneous coronary intervention versus 40% CABG. A reanalysis of this trial comparing percutaneous coronary intervention with CABG suggested that percutaneous coronary intervention offered no benefit but that coronary artery bypass graft surgery (CABG) might.18 More recently, the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo V (DECREASE-V) pilot study, a randomized trial of coronary revascularization or not in high-risk patients with demonstrable ischemia, including 3-vessel disease and left main stem disease, before major vascular surgery, showed no benefit for the patients who underwent preoperative revascularization.19 Again, the method of revascularization strategy was not randomized and was 65% percutaneous coronary intervention versus 35% CABG. Although these data are limited, they suggest that preoperative revascularization in general is not beneficial. They also suggest that if preoperative revascularization is to be performed, methods that do not involve stenting such as balloon angioplasty or CABG may be preferable. The second situation, which is becoming increasingly common, occurs when a patient with previous coronary stenting requires noncardiac surgery. In this situation, it is important to know the indication for stenting, the date of implantation, and the type(s) of stent(s) used, as well as the patient’s current OAA therapy and proposed duration. An assessment of the risks of the proposed surgery by the surgeon and anesthetist and of the likelihood and importance of possible stent thrombosis, preferably in conjunction with a cardiologist (ideally the cardiologist who implanted the stent), then needs to be undertaken. As an aid to this assessment, we have adapted a table from Albaladejo et al20 and incorporated the latest recommendations (Table 2). This table and the accompanying algorithm (the Figure) are based on consensus opinion and therefore may change as further data become available.
|
|
When possible, surgery should be delayed until the patient is outside the recommended period of dual antiplatelet therapy, as determined by the stent and lesion characteristics. This would mean that surgery should be delayed until 6 weeks after implantation of a bare-metal stent and 1 year after implantation of a DES. In reality, the recommendation for a 6-week delay with a bare-metal stent is to ensure that the patient completes a 4-week course of dual antiplatelet therapy because the patient will need 5 to 10 days (depending on the platelet half-life) for the effect of the antiplatelet agents to wear off before surgery.21 Patients in whom noncardiac surgery is carried out within these time periods are deemed at high risk of stent thrombosis. Patients in whom noncardiac surgery is performed outside these time periods may still be at high risk of stent thrombosis, depending on factors related to their coronary anatomy and their clinical characteristics. Stent thrombosis is more likely to occur in patients who have had stenting of ostial lesions, bifurcation lesions, lesions in small vessels, multiple lesions, or long lesions. In addition, patients with diabetes mellitus or renal impairment or patients in whom the indication for stenting was an acute myocardial infarction or an acute coronary syndrome are at higher risk of stent thrombosis.
When assessing the bleeding risk for an operative procedure, one needs to consider not only the actual blood loss associated with the procedure in terms of anemia and need for transfusion but also the consequences of the bleeding in terms of its site. For instance, even minor bleeding may be intolerable during or after certain ophthalmologic and intracranial surgery. Often, the decision to operate while antiplatelet agents are continued will be a matter of personal judgment. For many operative procedures, there is no evidence and no recommendations to aid in this decision.22 Dual OAA therapy usually consists of aspirin and a thienopyridine (most frequently clopidogrel). It is generally accepted that there are more perioperative bleeding problems with thienopyridines than aspirin23; therefore, if 1 OAA is stopped, it is generally the thienopyridine.
When possible, OAAs should be continued throughout the perioperative period, and if stopped, they should be stopped for as short a period as possible before surgery and restarted as soon as possible after surgery. In addition, for patients at high risk of stent thrombosis, consideration should be given to substituting oral agents with a shorter-acting, intravenous glycoprotein IIb/IIIa inhibitor during the perioperative period. However, the evidence for this use of alternative antiplatelet agents is largely anecdotal.24 In patients for whom noncardiac surgery is planned soon but preoperative revascularization is considered essential, consideration should first be given to modes of revascularization that do not involve stents such as CABG25 or balloon angioplasty,26 although the latter may necessitate stenting if there is a complication. If stenting is deemed necessary, there may be a place for newer stents that encourage rapid endothelialization,27 thereby possibly allowing surgery to be performed earlier. However, there is no evidence yet that these theoretical benefits will be realized. Along the same lines, absorbable stents are currently in development.28 However, although they may remove the risk of late thrombosis, they probably will not solve the problem of the risk of early surgery. If, despite all of the above precautions, stent thrombosis should occur during the perioperative period, the correct treatment is almost certainly urgent percutaneous coronary intervention29 because recent surgery usually rules out the use of thrombolytic therapy.
|
How Should We Manage Our Patient’s Antiplatelet Therapy? |
|---|
|
TopIntroductionNoncardiac Surgery and Stent...Likely Clinical SettingsHow Should We Manage...ConclusionsReferences |
|---|
Our patient’s clopidogrel was discontinued for 5 days before the biopsy and restarted with a loading dose of 300 mg on the first postoperative day. Aspirin was continued throughout.
|
Conclusions |
|---|
|
TopIntroductionNoncardiac Surgery and Stent...Likely Clinical SettingsHow Should We Manage...ConclusionsReferences |
|---|
The management of the increasingly common and complex group of patients with coronary stents who require noncardiac surgery requires a multidisciplinary approach to avoid potentially catastrophic outcomes. We have outlined some guidelines to aid in the decision-making process that should be undertaken before such patients are schedule for surgery.
|
Acknowledgments |
|---|
Disclosures
None.
|
References |
|---|
|
TopIntroductionNoncardiac Surgery and Stent...Likely Clinical SettingsHow Should We Manage...ConclusionsReferences |
|---|
- Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293: 2126–2130.
[Abstract/Free Full Text] - Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, Carrozza JP Jr, Chauhan MS, Rodriguez O, Kuntz RE. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001; 103: 1967–1971.
[Abstract/Free Full Text] - Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007; 356: 1009–1019.
[Abstract/Free Full Text] - Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007; 115: 813–818.
[Abstract/Free Full Text] - Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115: 2344–2351.
[Abstract/Free Full Text] - Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, Benzuly KH, Flaherty JD, Ricciardi MJ, Bennett CL, Williams DO. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007; 297: 1992–2000.
[Abstract/Free Full Text] - Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, Granada JF, Marulkar S, Nassif D, Cohen DJ, Kleiman NS. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007; 297: 2001–2009.
[Abstract/Free Full Text] - Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol. 2000; 35: 1288–1294.
[Abstract/Free Full Text] - Vicenzi MN, Meislitzer T, Heitzinger B, Halaj M, Fleisher LA, Metzler H. Coronary artery stenting and non-cardiac surgery: a prospective outcome study. Br J Anaesth. 2006; 96: 686–693.
[Abstract/Free Full Text] - Wilson SH, Fasseas P, Orford JL, Lennon RJ, Horlocker T, Charnoff NE, Melby S, Berger PB. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol. 2003; 42: 234–240.
[Abstract/Free Full Text] - Sharma AK, Ajani AE, Hamwi SM, Maniar P, Lakhani SV, Waksman R, Lindsay J. Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv. 2004; 63: 141–145.[CrossRef][Medline]
[Order article via Infotrieve]
- Reddy PR, Vaitkus PT. Risks of noncardiac surgery after coronary stenting. Am J Cardiol. 2005; 95: 755–757.[CrossRef][Medline]
[Order article via Infotrieve]
- Leibowitz D, Cohen M, Planer D, Mosseri M, Rott D, Lotan C, Weiss AT. Comparison of cardiovascular risk of noncardiac surgery following coronary angioplasty with versus without stenting. Am J Cardiol. 2006; 97: 1188–1191.[CrossRef][Medline]
[Order article via Infotrieve]
- Compton PA, Zankar AA, Adesanya AO, Banerjee S, Brilakis ES. Risk of noncardiac surgery after coronary drug-eluting stent implantation. Am J Cardiol. 2006; 98: 1212–1213.[CrossRef][Medline]
[Order article via Infotrieve]
- Schouten O, van Domburg RT, Bax JJ, de Jaegere PJ, Dunkelgrun M, Feringa HH, Hoeks SE, Poldermans D. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol. 2007; 49: 122–124.
[Free Full Text] - Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann KE, Fleisher LA, Froehlich JB, Gusberg RJ, Leppo JA, Ryan T, Schlant RC, Winters WL Jr, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation. 2002; 105: 1257–1267.
[Free Full Text] - McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, Pierpont G, Santilli S, Rapp J, Hattler B, Shunk K, Jaenicke C, Thottapurathu L, Ellis N, Reda DJ, Henderson WG. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med. 2004; 351: 2795–2804.
[Abstract/Free Full Text] - Ward HB, Kelly RF, Thottapurathu L, Moritz TE, Larsen GC, Pierpont G, Santilli S, Goldman S, Krupski WC, Littooy F, Reda DJ, McFalls EO. Coronary artery bypass grafting is superior to percutaneous coronary intervention in prevention of perioperative myocardial infarctions during subsequent vascular surgery. Ann Thorac Surg. 2006; 82: 795–800.
[Abstract/Free Full Text] - Poldermans D, Schouten O, Vidakovic R, Bax JJ, Thomson IR, Hoeks SE, Feringa HH, Dunkelgrun M, de Jaegere P, Maat A, van Sambeek MR, Kertai MD, Boersma E. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study. J Am Coll Cardiol. 2007; 49: 1763–1769.
[Abstract/Free Full Text] - Albaladejo P, Marret E, Piriou V, Samama CM. Management of oral antiplatelet treatment for patients with coronary stents [in French]. Ann Fr Anesth Reanim. 2006; 25: 796–798.[Medline]
[Order article via Infotrieve]
- Chu MW, Wilson SR, Novick RJ, Stitt LW, Quantz MA. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg. 2004; 78: 1536–1541.
[Abstract/Free Full Text] - Samama CM, Bastien O, Forestier F, Denninger MH, Isetta C, Juliard JM, Lasne D, Leys D, Mismetti P. Antiplatelet agents in the perioperative period: expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR) 2001: summary statement. Can J Anaesth. 2002; 49: S26–S35.[Medline]
[Order article via Infotrieve]
- Lecompte T, Hardy JF. Antiplatelet agents and perioperative bleeding. Can J Anaesth. 2006; 53 (suppl): S103–S112.
[Abstract/Free Full Text] - Broad L, Lee T, Conroy M, Bolsin S, Orford N, Black A, Birdsey G. Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery. Br J Anaesth. 2007; 98: 19–22.
[Abstract/Free Full Text] - Eagle KA, Rihal CS, Mickel MC, Holmes DR, Foster ED, Gersh BJ. Cardiac risk of noncardiac surgery: influence of coronary disease and type of surgery in 3368 operations: CASS Investigators and University of Michigan Heart Care Program: Coronary Artery Surgery Study. Circulation. 1997; 96: 1882–1887.
[Abstract/Free Full Text] - Brilakis ES, Orford JL, Fasseas P, Wilson SH, Melby S, Lennon RJ, Berger PB. Outcome of patients undergoing balloon angioplasty in the two months prior to noncardiac surgery. Am J Cardiol. 2005; 96: 512–514.[CrossRef][Medline]
[Order article via Infotrieve]
- Aoki J, Serruys PW, van Beusekom H, Ong AT, McFadden EP, Sianos G, van der Giessen WJ, Regar E, de Feyter PJ, Davis HR, Rowland S, Kutryk MJ. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth–First In Man) Registry. J Am Coll Cardiol. 2005; 45: 1574–1579.
[Abstract/Free Full Text] - Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, Erne P, Haude M, Heublein B, Horrigan M, Ilsley C, Bose D, Koolen J, Luscher TF, Weissman N, Waksman R. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet. 2007; 369: 1869–1875.[CrossRef][Medline]
[Order article via Infotrieve]
- Berger PB, Bellot V, Bell MR, Horlocker TT, Rihal CS, Hallett JW, Dalzell C, Melby SJ, Charnoff NE, Holmes DR Jr. An immediate invasive strategy for the treatment of acute myocardial infarction early after noncardiac surgery. Am J Cardiol. 2001; 87: 1100–1102, A1106, A1109.
Related Article:
-
Issue Highlights
Circulation 2007 116: 1755.[Full Text]
This article has been cited by other articles:
 |
|
 |
|
  J. Nappi Benefits and limitations of current antiplatelet therapies Am. J. Health Syst. Pharm., July 1, 2008; 65(13_Supplement_5): S5 - S10. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||